# Cryoport, Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/fi/companies/Cryoport, Inc.).

## Overview

Cryoport, Inc. provides temperature-controlled supply chain solutions for the life sciences industry, with a particular focus on cell and gene therapies. The company combines logistics, biostorage, bioservices, cryopreservation, and cryogenic equipment manufacturing to help customers move and store sensitive biological materials under tightly regulated conditions.

## Products & services

• BioLogistics Solutions for temperature-controlled transport and handling
• BioStorage Solutions for secure biological storage
• BioServices Solutions and cryopreservation services
• Cryogenic systems manufacturing: freezers, dewars, accessories
• Cryoportal digital logistics management platform
• Chain of Compliance quality and regulatory support

- **Life Sciences Services** (54.8%) — Temperature-controlled logistics, biostorage, bioservices, and cryopreservation for life science customers.
- **Life Sciences Products** (45.2%) — Cryogenic systems such as freezers, dewars, and related accessories sold directly or through distributors.

- BioLogistics Solutions for temperature-controlled transport and handling
- BioStorage Solutions for secure biological storage
- BioServices Solutions and cryopreservation services
- Cryogenic systems manufacturing: freezers, dewars, accessories
- Cryoportal digital logistics management platform
- Chain of Compliance quality and regulatory support

## Customers

Cryoport sells primarily to life sciences customers that need validated, compliant handling of sensitive biological materials. Its customer base includes biotech and pharmaceutical companies, CROs, CDMOs, central laboratories, fertility clinics, animal health companies, universities, and research facilities, with especially strong exposure to cell and gene therapy programs.

- **Biotechnology and pharmaceutical companies** (primary) — Buy logistics, storage, and cryopreservation services for clinical and commercial biologics, especially CGT programs.
- **Contract research organizations and CDMOs** (primary) — Use Cryoport to move trial materials and support outsourced development/manufacturing workflows.
- **Clinical trial sponsors** (primary) — Need compliant, traceable transport for patient- or donor-derived materials across global trials.
- **Fertility and reproductive medicine providers** (secondary) — Buy cryopreservation and temperature-controlled handling for reproductive materials.
- **Animal health and research institutions** (secondary) — Purchase cryogenic systems and logistics for biological samples and research materials.

- Biotech and pharmaceutical companies developing cell and gene therapies
- CROs and CDMOs needing validated sample and material logistics
- Central laboratories and research facilities shipping sensitive specimens
- Fertility clinics and cryopreservation users requiring controlled storage
- Animal health customers buying cryogenic storage and transport equipment

## Geography

Cryoport generates most of its revenue in the Americas, with meaningful exposure to EMEA and APAC. The company operates globally and uses its international footprint to support regulated life sciences supply chains, while foreign exchange and local compliance requirements affect execution and margins.

- **Americas** (74.5%)
- **Europe, the Middle East and Africa (EMEA)** (14.3%)
- **Asia Pacific (APAC)** (11.2%)

- Americas accounted for 74.5% of 2025 revenue
- EMEA accounted for 14.3% of 2025 revenue
- APAC accounted for 11.2% of 2025 revenue
- International sales expose the company to FX and trade/regulatory risk
- DHL partnership is intended to strengthen EMEA and APAC reach

## Strategy

Cryoport is focused on deepening its position in cell and gene therapy supply chains by combining digital logistics, compliance, and global infrastructure. Management is also investing in technology, geographic expansion, and new supply chain initiatives while using the CRYOPDP divestiture and DHL partnership to sharpen its international operating model.

- **Grow in cell and gene therapy supply chains** (medium-term) — CGT programs require specialized, validated logistics and create sticky customer relationships.
- **Digitize and integrate the operating platform** (medium-term) — A unified digital layer improves visibility, compliance, and execution across global shipments and storage.
- **Rebalance the international network after CRYOPDP divestiture** (short-term) — The divestiture frees capital and allows focus on higher-value services and strategic partnerships.

- Expand CGT-focused supply chain solutions and customer penetration
- Use Cryoportal and ETG to unify digital monitoring and analytics
- Strengthen global infrastructure and regulated compliance capabilities
- Leverage DHL partnership to improve EMEA and APAC execution
- Invest in new platforms such as IntegriCell, CryoVerse, and Bioservices

## Risks

Cryoport faces execution risk from its dependence on regulated life sciences demand, especially CGT programs that can be delayed by funding or clinical setbacks. International exposure adds FX, trade, and geopolitical risk, while the company also remains vulnerable to customer concentration, government funding disruptions, and the need to keep investing before reaching sustained profitability.

- **Dependence on cell and gene therapy program activity** [high] — Clinical and commercial programs can be delayed, canceled, or scaled back, reducing demand for specialized logistics and storage.
- **Foreign currency and international operating risk** [medium] — Revenue and costs in Europe and Asia are exposed to exchange-rate swings, local regulation, and geopolitical disruption.
- **Customer concentration** [medium] — A single customer represented 10.2% of total revenue in 2025, which can create volatility if volumes change.
- **U.S. federal funding disruption** [medium] — Some customers rely on federal funding or agency oversight, and shutdowns can delay purchasing decisions.
- **Need for continued external capital** [high] — The company expects near-term operating losses while investing in growth, which may require equity or debt financing.

- CGT program delays can reduce logistics and equipment demand
- International FX and trade rules can pressure margins and cash flow
- Customer concentration can create volatility in segment revenue
- Government shutdowns can delay customer purchasing decisions
- Ongoing losses may require additional capital or financing

## Accounting

Revenue is recognized when control transfers, so shipment timing and delivery terms can shift revenue between periods. Investors should also watch discontinued operations from the CRYOPDP divestiture, goodwill impairment risk in acquired assets such as MVE, and the effect of stock compensation, contingent consideration, and foreign currency on reported results.

- **Revenue recognition timing** — Quarterly revenue comparability
- **Discontinued operations** — Segment and consolidated comparability
- **Goodwill impairment** — Non-cash earnings volatility
- **Contingent consideration and fair value estimates** — Reported earnings and balance sheet values

- Revenue recognition depends on delivery and transfer of control
- Discontinued operations affect comparability after the CRYOPDP sale
- Goodwill impairment can create large non-cash charges
- Contingent consideration and fair value changes can move earnings
- FX translation affects international revenue and expenses

---

*Last updated: 2026-04-28T19:59:52.108677+00:00*